Browsing by Author Karagiannis, A.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jump to: Α Β Γ Δ Ε Ζ Η Θ Ι Κ Λ Μ Ν Ξ Ο Π Ρ Σ Τ Υ Φ Χ Ψ Ω
or enter first few letters:  
View Option
Showing results 15 to 24 of 24 < previous 
TitleAuthor(s)Issue date???itemlist.???
Percutaneous transluminal renal angioplasty in patients with renovascular hypertension: long-term resultsKaragiannis, A.; Douma, S.; Voyiatzis, K.; Petidis, K.; Athyros, V. G.; Vizantiadis, A.; Voujiouklis, N.; Zafiriades, E.; Efremidis, S.; Zamboulis, C.24-Nov-2015-
Prevalence of vascular disease in metabolic syndrome using three proposed definitionsAthyros, V. G.; Ganotakis, E. S.; Elisaf, M. S.; Liberopoulos, E. N.; Goudevenos, I. A.; Karagiannis, A.24-Nov-2015-
The role of renin-angiotensin system inhibition in the treatment of hypertension in metabolic syndrome: are all the angiotensin receptor blockers equal?Karagiannis, A.; Mikhailidis, D. P.; Athyros, V. G.; Kakafika, A. I.; Tziomalos, K.; Liberopoulos, E. N.; Florentin, M.; Elisaf, M. S.24-Nov-2015-
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT studyAthyros, V. G.; Giouleme, O.; Ganotakis, E. S.; Elisaf, M. S.; Tziomalos, K.; Vassiliadis, T.; Liberopoulos, E. N.; Theocharidou, E.; Karagiannis, A.; Mikhailidis, D. P.24-Nov-2015-
Should atenolol still be recommended as first-line therapy for primary hypertension?Karagiannis, A.; Athyros, V. G.; Papageorgiou, A.; Tziomalos, K.; Elisaf, M. S.24-Nov-2015-
Statin treatment may be beneficial to both the kidneys and the heartAthyros, V. G.; Karagiannis, A.; Liberopoulos, E. N.; Elisaf, M. S.; Mikhailidis, D. P.24-Nov-2015-
Statin-based treatment for cardiovascular risk and non-alcoholic fatty liver disease. Killing two birds with one stone?Athyros, V. G.; Tziomalos, K.; Daskalopoulos, G. N.; Karagiannis, A.; Mikhailidis, D. P.24-Nov-2015-
Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease PatientsAthyros, V. G.; Kakafika, A. I.; Papageorgiou, A. A.; Pagourelias, E. D.; Savvatianos, S. D.; Elisaf, M. S.; Karagiannis, A.; Tziomalos, K.; Mikhailidis, D. P.24-Nov-2015-
Statins and renal function. Is the compound and dose making a difference?Athyros, V. G.; Karagiannis, A.; Kakafika, A.; Elisaf, M. S.; Mikhailidis, D. P.24-Nov-2015-
Targeting vascular risk in patients with metabolic syndrome but without diabetesAthyros, V. G.; Mikhailidis, D. P.; Papageorgiou, A. A.; Didangelos, T. P.; Peletidou, A.; Kleta, D.; Karagiannis, A.; Kakafika, A. I.; Tziomalos, K.; Elisaf, M. S.24-Nov-2015-